( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Sepsis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets's offering. This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Sepsis Emerging Drugs Thymosin Alpha 1: Sci Clone Pharmaceuticals Thymosin alpha 1, referred to as thymalfasin, is a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement.
SciClone developed and launched Thymosin alpha 1, under the trade name Zadaxin, for the treatment of hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections. The drug is also being developed for the treatment of COVID 2019 infections. Scientific and clinical studies have shown that Thymosin alpha 1 helps to stimulate and direct the body's immune response to eradicate infectious diseases, such as HBV, HCV, bacterial, and fungal infections; to fight certain cancers such as melanoma and liver cancer; and to enhance response to vaccines.
Clinical trials have shown that Thymosin alpha 1 improves survival in patients in intensive care units being treated for sepsis from sever.
